Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -136.01% is 92% above its 2-year average of -1743.43%, near the high end of its 2-year range (-3340.37%–57.27%).
89.56% above its 12-month average of -1303.16%.
Reported quarterly EBITDA margin; no daily interpolation. Q1 FY2022 (2022-03-31): -865.11%.
EBITDA MARGIN
-136.01%
EBITDA MARGIN AVG TTM
-1303.16%
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+89.56%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Elicio Therapeutics, Inc.
Market Cap
$36.61M
EBITDA Margin
-136.01%
TTM Avg
-1303.16%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$36.32M
EBITDA Margin
-127.12%
TTM Avg
-129.61%
3Y Avg
-125.08%
5Y Avg
-93.97%
Market Cap
$35.89M
EBITDA Margin
-6.58%
TTM Avg
-1.77%
3Y Avg
-0.14%
5Y Avg
1.64%
Market Cap
$37.67M
EBITDA Margin
-1929.22%
TTM Avg
-1308.49%
3Y Avg
-1783.80%
5Y Avg
-1343.37%
Market Cap
$38.34M
EBITDA Margin
6.14%
TTM Avg
3.48%
3Y Avg
3.86%
5Y Avg
5.21%
Market Cap
$38.41M
EBITDA Margin
-27375.58%
TTM Avg
-138216.12%
3Y Avg
-92142.37%
5Y Avg
-55460.65%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Elicio Therapeutics, Inc. (ELTX) | $36.61M | -136.01% | -1303.16% | N/A | N/A |
| BriaCell Therapeutics Corp. (BCTX)vs › | $36.37M | N/A | N/A | N/A | N/A |
| Elutia Inc (ELUT)vs › | $36.32M | -127.12% | -129.61% | -125.08% | -93.97% |
| HeartBeam, Inc. (BEAT)vs › | $36.31M | 31.08% | 27.03% | 24.58% | 21.46% |
| DocGo Inc. (DCGO)vs › | $36.05M | -22.81% | -7.79% | -0.80% | -0.97% |
| Accuray Incorporated (ARAY)vs › | $35.89M | -6.58% | -1.77% | -0.14% | 1.64% |
| Edesa Biotech, Inc. (EDSA)vs › | $37.67M | -1929.22% | -1308.49% | -1783.80% | -1343.37% |
| Harvard Bioscience, Inc. (HBIO)vs › | $38.34M | 6.14% | 3.48% | 3.86% | 5.21% |
| Incannex Healthcare Limited (IXHL)vs › | $38.41M | -27375.58% | -138216.12% | -92142.37% | -55460.65% |
| Grace Therapeutics, Inc. (GRCE)vs › | $33.52M | -7905.63% | -7905.63% | -7905.63% | -7905.63% |
Gross Margin
0.0%
EBITDA Margin
-136.0%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2022-03-31 | -865.11% |
| 2021-12-31 | 57.27% |
| 2021-09-30 | -1064.45% |
| 2021-06-30 | -3340.37% |
| 2020-12-31 | -2985.62% |
| 2020-09-30 | -1383.80% |
| 2020-06-30 | -2345.54% |
| 2019-12-31 | -2019.83% |
